NASDAQ:LMNL   Liminal BioSciences Inc
I called Liminal BioSciences Inc (NASDAQ:LMNL) recently at $4. 40 as a potential big runner due to the PDUFA catalyst. On Friday, just a few minutes before the close, the stock was halted and the U.S. Food & Drug Administration (FDA) announced the approval of Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics Inc. , holder of the biological license application ("BLA") for Ryplazim®. With this approval, Ryplazim® becomes the first FDA approved therapy for this rare genetic disorder. The stock closed the after-hours trading gaining more than 55% with 8.2M shares traded. Congratulations to those who bought and profited on LMNL in after-hours, further gains are by no means guaranteed and it never hurts to lock profits in after being up almost 70%. Let's see that $7 break on Monday and see if the stock wants more gains, consolidation, or a pull back.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.